NR3C2 and chronic kidney disease: In the past few years, evidence has emerged for newer interventions; sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i), non‐steroidal selective mineralocorticoid receptor antagonist (nsMRA) finerenone, and glucagon‐like peptide 1 receptor agonist (GLP1 RA) that can further reduce the risk of ESKD and CVD (including heart failure) in people with CKD.8, 9, 10